A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Azacitidine / adverse effects Bone Marrow Granulocyte-Macrophage Colony-Stimulating Factor Hematopoietic Stem Cell Transplantation / adverse effects Humans Leukemia, Myeloid, Acute / chemically induced Myelodysplastic Syndromes / diagnosis Recurrence
AML Azacitidine GM-CSF MDS Post-transplant maintenance

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 22 7 2021
medline: 15 4 2022
entrez: 21 7 2021
Statut: ppublish

Résumé

Relapse is the most common cause of treatment failure following allogeneic blood or marrow transplantation (alloBMT) for AML or MDS. Post-transplant maintenance therapies may prevent relapse. We conducted a phase II trial combining azacitidine (AZA) with GM-CSF in non-relapsed, post-transplant patients with AML or MDS. Patients received escalating doses of AZA to a maximum of 75 mg/m

Identifiants

DOI: 10.1080/10428194.2021.1948029 PMID: 34284701 PMC: PMC9195564
pubmed: 34284701
doi: 10.1080/10428194.2021.1948029
pmc: PMC9195564
mid: NIHMS1809185
doi:

Substances chimiques

Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1
Azacitidine M801H13NRU

Types de publication

Clinical Trial, Phase II Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3181-3191

Subventions

Organisme : NCI NIH HHS
ID : P01 CA225618
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

N Engl J Med. 1995 Jan 26;332(4):217-23
pubmed: 7808487
Leuk Lymphoma. 2020 Dec;61(12):2839-2849
pubmed: 32650686
J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749
pubmed: 31200351
Blood Adv. 2018 Aug 28;2(16):2127-2135
pubmed: 30143527
Blood Adv. 2020 Oct 27;4(20):5078-5088
pubmed: 33080006
J Clin Oncol. 2009 Sep 20;27(27):4570-7
pubmed: 19652066
Cell Growth Differ. 2002 Jun;13(6):275-83
pubmed: 12114217
Leuk Lymphoma. 2018 Dec;59(12):2836-2841
pubmed: 29616863
Biol Blood Marrow Transplant. 2014 Oct;20(10):1566-72
pubmed: 24972249
Br J Haematol. 2005 Mar;128(6):853-62
pubmed: 15755292
Biol Blood Marrow Transplant. 2011 May;17(5):754-8
pubmed: 20951817
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
Eur J Haematol. 2015 Nov;95(5):484-5
pubmed: 26104906
Haematologica. 2016 May;101(5):607-16
pubmed: 26819054
J Clin Oncol. 2019 Jul 1;37(19):1604-1607
pubmed: 31034300
Leukemia. 2012 Mar;26(3):381-9
pubmed: 21886171
Biol Blood Marrow Transplant. 2020 Feb;26(2):300-306
pubmed: 31550496
Haematologica. 2017 Feb;102(2):391-400
pubmed: 27846611
Cancer. 2010 Dec 1;116(23):5420-31
pubmed: 20672358
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Blood. 2007 Apr 1;109(7):2791-3
pubmed: 17119111
Blood. 2012 Apr 12;119(15):3571-7
pubmed: 22262762
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
JAMA. 2009 Jun 10;301(22):2349-61
pubmed: 19509382
Blood. 2009 Apr 30;113(18):4179-87
pubmed: 19008455
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2006 May 1;107(9):3481-5
pubmed: 16455952
Leukemia. 2003 Sep;17(9):1738-52
pubmed: 12970773
Biol Blood Marrow Transplant. 2018 Oct;24(10):2017-2024
pubmed: 29933073
Bone Marrow Transplant. 2016 May;51(5):663-7
pubmed: 26437060
Leukemia. 1996 Nov;10(11):1687-91
pubmed: 8892667
Leukemia. 2016 Jul;30(7):1456-64
pubmed: 27012865
Bone Marrow Transplant. 2015 Aug;50(8):1063-8
pubmed: 26030052
Biol Blood Marrow Transplant. 2018 Jun;24(6):1232-1236
pubmed: 28918304
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
J Clin Oncol. 2015 Oct 1;33(28):3152-61
pubmed: 26261255
Blood. 2019 Mar 28;133(13):1457-1464
pubmed: 30630862
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
JAMA. 2011 Nov 2;306(17):1874-83
pubmed: 22045765
Blood Adv. 2020 Nov 10;4(21):5580-5588
pubmed: 33170934
Blood. 2010 Mar 4;115(9):1850-7
pubmed: 20032503
Biol Blood Marrow Transplant. 2016 Feb;22(2):385-390
pubmed: 26363443
Leuk Res. 2017 Oct;61:25-32
pubmed: 28869816
Blood. 2012 Mar 22;119(12):2943-8
pubmed: 22323482
Cell. 1979 Aug;17(4):771-9
pubmed: 90553
Leukemia. 2012 Aug;26(8):1804-11
pubmed: 22343522
Biol Blood Marrow Transplant. 2012 Feb;18(2):280-8
pubmed: 21810400
Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8
pubmed: 25239228
Blood. 2004 Jul 15;104(2):579-85
pubmed: 15039286
Br J Haematol. 1988 Nov;70(3):317-20
pubmed: 3061443
J Clin Oncol. 2020 Apr 20;38(12):1273-1283
pubmed: 31860405
Biol Blood Marrow Transplant. 2015 Oct;21(10):1761-9
pubmed: 26055299
Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50
pubmed: 18489989
Biol Blood Marrow Transplant. 2019 Oct;25(10):1984-1992
pubmed: 31212080
Blood. 2007 May 1;109(9):3658-66
pubmed: 17213292
Blood Adv. 2019 Sep 10;3(17):2608-2616
pubmed: 31492679
Leuk Res. 2011 Jan;35(1):87-94
pubmed: 20598742
Bone Marrow Transplant. 2012 Dec;47(12):1535-7
pubmed: 22659680

Auteurs

Jonathan A Webster (JA)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID: 0000-0003-3647-6345

Meera Yogarajah (M)

SSM Medical Group, St. Charles, MO, USA.

Marianna Zahurak (M)

Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Heather Symons (H)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Amy E Dezern (AE)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Ivana Gojo (I)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Gabrielle T Prince (GT)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Jillian Morrow (J)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Richard J Jones (RJ)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

B Douglas Smith (BD)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Margaret Showel (M)

Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Ribonucléosides › Cytidine › Azacitidine › A phase II study of azacitidine in combination...
Recherchemedicale.com › Systèmes sanguin et immunitaire › Système immunitaire › Moelle osseuse › A phase II study of azacitidine in combination...
Recherchemedicale.com › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de croissance hématopoïétique › Facteurs de stimulation des colonies › Facteur de stimulation des colonies de granulocytes et de macrophages › A phase II study of azacitidine in combination...
Recherchemedicale.com › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › A phase II study of azacitidine in combination...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A phase II study of azacitidine in combination...
Recherchemedicale.com › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › A phase II study of azacitidine in combination...
Recherchemedicale.com › Hémopathies et maladies lymphatiques › Hémopathies › Maladies de la moelle osseuse › Syndromes myélodysplasiques › A phase II study of azacitidine in combination...
Recherchemedicale.com › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › A phase II study of azacitidine in combination...